公开(公告)号：US20060046249A1

公开(公告)日：2006-03-02

申请号：US10501035

申请日：2003-01-17

申请人： Fei Huang ,  Craig Fairchild ,  Francis Lee ,  Peter Shaw

发明人： Fei Huang ,  Craig Fairchild ,  Francis Lee ,  Peter Shaw

IPC分类号： C12Q1/68 ,  C07H21/04

CPC分类号： G01N33/5011 ,  C12Q1/6837 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/5023 ,  G01N2333/91215 ,  G01N2800/52 ,  G16B20/00

摘要： The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compounds that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compounds. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.

摘要翻译： 本发明描述了已被发现与将细胞例如结肠细胞系相对固有的敏感性或抗性与与酪氨酸激酶相互作用并抑制酪氨酸激酶的化合物进行治疗相关的多核苷酸和多肽。 已经通过加权投票交叉验证程序显示了这些多核苷酸和多肽在预测结肠细胞系对这些化合物的固有抗性和敏感性方面具有实用性。 其表达水平与药物敏感性或抗性高度相关的这样的多核苷酸和多肽包括可用于预测药物反应的方法中的多核苷酸和多肽的预测物或标志物组，以及作为疾病管理中的预后或诊断指标，特别是在其中 通过src酪氨酸激酶信号传导src酪氨酸激酶途径参与疾病过程。

公开(公告)号：US20060019284A1

公开(公告)日：2006-01-26

申请号：US11169041

申请日：2005-06-28

申请人： Fei Huang ,  Karen Reeves ,  Xia Han ,  Craig Fairchild ,  Peter Shaw

发明人： Fei Huang ,  Karen Reeves ,  Xia Han ,  Craig Fairchild ,  Peter Shaw

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158

摘要： The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compounds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

摘要翻译： 本发明描述了已经发现与将细胞（例如肺细胞系）的相对固有敏感性或抗性相关联的化合物与与蛋白酪氨酸激酶相互作用并调节，例如抑制蛋白质酪氨酸激酶（例如， ，Src家族酪氨酸激酶的成员，例如Src，Fgr，Fyn，是，Blk，Hck，Lck和Lyn，以及其它蛋白酪氨酸激酶，包括Bcr-abl，Jak，PDGFR，c-kit和 以弗所 已经通过加权投票交叉验证程序显示了这些多核苷酸可用于预测肺细胞系对化合物的抵抗力和敏感性。 一些多核苷酸的表达水平通过用特定蛋白酪氨酸激酶抑制剂化合物的治疗来调节，因此表明这些多核苷酸参与蛋白酪氨酸激酶信号转导途径，例如Src酪氨酸激酶。 这些多核苷酸的表达水平与药物敏感性或抗性高度相关并且通过用化合物处理而被调节的多核苷酸包括用于预测药物反应的方法中的多核苷酸预测物或标志物组，以及疾病管理中的预后或诊断指标，特别是在那些 疾病领域，例如肺癌，其中通过蛋白酪氨酸激酶途径的信号，例如Src酪氨酸激酶途径参与疾病过程。

公开(公告)号：US20060029944A1

公开(公告)日：2006-02-09

申请号：US11072175

申请日：2005-03-04

申请人： Fei Huang ,  Xia Han ,  Karen Reeves ,  Lukas Amler ,  Craig Fairchild ,  Francis Lee ,  Peter Shaw

发明人： Fei Huang ,  Xia Han ,  Karen Reeves ,  Lukas Amler ,  Craig Fairchild ,  Francis Lee ,  Peter Shaw

IPC分类号： C12Q1/68 ,  C07H21/04

CPC分类号： C07K14/47 ,  A61K38/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158

摘要： The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

摘要翻译： 本发明描述了已被发现与多种细胞相关的细胞（例如，乳腺细胞系）与用蛋白酪氨酸激酶相互作用并调节，例如抑制蛋白质酪氨酸激酶（例如， ，Src家族酪氨酸激酶的成员，例如Src，Fgr，Fyn，是，Blk，Hck，Lck和Lyn，以及其它蛋白酪氨酸激酶，包括Bcr-abl，Jak，PDGFR，c-kit和 Eph受体。 已经通过加权投票交叉验证程序显示了这些多核苷酸可用于预测乳腺细胞系对化合物的抵抗力和敏感性。 一些多核苷酸的表达水平或磷酸化状态通过用特定蛋白质酪氨酸激酶抑制剂化合物的处理来调节，从而表明这些多核苷酸参与蛋白酪氨酸激酶信号转导途径，例如Src酪氨酸激酶。 这些多核苷酸的表达水平与药物敏感性或抗性高度相关并且通过用化合物处理而被调节的多核苷酸包括用于预测药物反应的方法中的多核苷酸预测物或标志物组，以及疾病管理中的预后或诊断指标，特别是在那些 疾病领域，例如乳腺癌，其中通过蛋白酪氨酸激酶途径的信号传导，例如Src酪氨酸激酶途径参与疾病过程。

公开(公告)号：US20070166704A1

公开(公告)日：2007-07-19

申请号：US10348119

申请日：2003-01-17

申请人： Fei Huang ,  Craig Fairchild ,  Francis Lee ,  Peter Shaw

发明人： Fei Huang ,  Craig Fairchild ,  Francis Lee ,  Peter Shaw

IPC分类号： C12Q1/68 ,  C07H21/04

CPC分类号： G01N33/5011 ,  C12Q1/6837 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/5023 ,  G01N2333/91215 ,  G01N2800/52 ,  G16B20/00

摘要： The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compounds that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compounds. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.

摘要翻译： 本发明描述了已被发现与将细胞例如结肠细胞系相对固有的敏感性或抗性与与酪氨酸激酶相互作用并抑制酪氨酸激酶的化合物进行治疗相关的多核苷酸和多肽。 已经通过加权投票交叉验证程序显示了这些多核苷酸和多肽在预测结肠细胞系对这些化合物的固有抗性和敏感性方面具有实用性。 其表达水平与药物敏感性或抗性高度相关的这样的多核苷酸和多肽包括可用于预测药物反应的方法的预测因子或标志物组，以及在疾病管理中的预后或诊断指标，特别是在信号传导 通过src酪氨酸激酶的酪氨酸激酶途径参与疾病过程。